Try our Advanced Search for more refined results

Celgene Paying Up To $2.6B In Jounce Cancer Collaboration

By Alex Wolf ( July 20, 2016, 7:23 PM EDT) -- Biopharmaceutical company Celgene Corp. is infusing privately held Jounce Therapeutics Inc. with an upfront payment of $225 million, a $36 million equity investment and up to an additional $2.3 billion in future payments to jointly develop and commercialize immuno-oncology treatments for patients with cancer, according to an announcement Tuesday....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!